Valuation: Evotec SE

Market Cap 883M 1.01B 815M 761M 1.43B 95.35B 1.47B 9.81B 3.79B 47.04B 3.79B 3.7B 163B P/E 2026 *
-6.99x
P/E 2027 * -25.4x
Enterprise Value 897M 1.02B 828M 774M 1.46B 96.89B 1.49B 9.97B 3.85B 47.8B 3.85B 3.76B 166B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 1.16x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-0.66%
1 week+5.27%
Current month-6.25%
1 month-6.69%
3 months+15.93%
6 months-9.17%
Current year-9.17%
1 week 4.67
Extreme 4.666
5.08
1 month 4.52
Extreme 4.516
5.33
Current year 4
Extreme 3.995
6.73
1 year 4
Extreme 3.995
7.84
3 years 4
Extreme 3.995
24.44
5 years 4
Extreme 3.995
45.83
10 years 3.64
Extreme 3.641
45.83
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO - 30/04/2026
Chief Operating Officer - 30/04/2026
Director TitleAgeSince
Director/Board Member 58 18/06/2019
Director/Board Member 64 31/05/2021
Director/Board Member 43 21/06/2022
Date Insider Type Main position Quantity % Market Cap.
06-14Sell

Chief Technology Officer

-119,900 0.0674%
05-19Fiscal year

Chief Technology Officer

12,462 0.0070%
05-03Buy 15,510 0.0087%
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%+5.27%-31.29%-75.98% 1.01B
+1.26%+5.98%-3.36%+2.36% 46.62B
-1.94%+11.81%+415.15%+608.50% 40.95B
-0.61%+12.95%+22.76%-13.93% 32.26B
-1.49%+3.52%+18.09%+60.32% 32.24B
+8.02%+6.35%+17.67%+34.73% 25.53B
+1.29%+12.00% - - 16.38B
+0.15%+13.28%+70.89%+123.33% 15.27B
+0.12%+4.69%+13.00%+17.43% 13.61B
-1.31%+4.59%+101.15%+93.70% 13.34B
Average +0.51%+11.06%+69.34%+94.50% 23.72B
Weighted average by Cap. +0.56%+11.56%+95.96%+139.04%

Financials

2026 *2027 *
Net sales 738M 842M 681M 636M 1.2B 79.64B 1.22B 8.19B 3.16B 39.29B 3.16B 3.09B 136B 818M 934M 755M 705M 1.33B 88.31B 1.36B 9.09B 3.51B 43.56B 3.51B 3.43B 151B
Net income -113M -129M -105M -97.61M -184M -12.23B -188M -1.26B -486M -6.03B -486M -475M -20.94B -30.42M -34.74M -28.08M -26.23M -49.37M -3.28B -50.49M -338M -130M -1.62B -130M -128M -5.63B
Net Debt 14.3M 16.33M 13.2M 12.33M 23.21M 1.54B 23.73M 159M 61.33M 762M 61.33M 59.99M 2.64B 69.32M 79.17M 64M 59.76M 113M 7.49B 115M 770M 297M 3.69B 297M 291M 12.82B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
30/06/26 4.950 -0.36% 485,913
29/06/26 €4.968 +1.26% 454,845
26/06/26 €4.906 +1.41% 459,786
25/06/26 €4.838 +0.58% 705,454
24/06/26 €4.810 +2.30% 1,002,560
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.968EUR
Average target price
6.443EUR
Spread / Average Target
+29.69%

Quarterly revenue - Rate of surprise